Vancouver, Canada, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: C...








    



            







    
        
            December 10, 2025 16:15 ET
        

        
             | Source:
            

                Clearmind Medicine Inc.
            
                

        
    

    

    

    





        
Vancouver, Canada, Dec.  10, 2025  (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, announced it will conduct a reverse share split of its issued and outstanding common shares, no par value, at a ratio of 1-for-40. The reverse split is being effected as part of the Company’s plan to regain compliance with the Nasdaq Minimum Bid Price Rule and will be effective commencing December 15, 2025.‍The reverse share split was approved by the Company' board of directors on November 12, 2025, in accordance with the Company’s articles of association.‍Following the implementation of the reverse split, the Company’s authorized share capital will remain unchanged, which as of the date hereof is unlimited. The reverse split will adjust the number of issued and outstanding Common Shares of the Company from 59,991,852 Common Shares to 1,499,796 Common Shares (subject to any further adjustments based on the treatment of fractional shares).‍No fractional Common Shares will be issued as a result of the reverse split. All fractional shares shall be rounded up to the nearest whole Common Share. In addition, a proportionate adjustment will be made to the per share exercise price and the number of Common Shares issuable upon the exercise of all outstanding options or warrants entitling the holders thereof to purchase Common Shares.About Clearmind Medicine Inc.  Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.  The Company’s intellectual portfolio currently consists of nineteen patent families including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.  Shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND" and the Frankfurt Stock Exchange under the symbol “CWY0.”  For further information visit: https://www.clearmindmedicine.com or contact:  Investor Relationsinvest@clearmindmedicine.com  Telephone: (604) 260-1566US: CMND@crescendo-ir.com  General InquiriesInfo@Clearmindmedicine.comwww.Clearmindmedicine.com  Forward-Looking Statements:  This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses effecting a reverse share split and plan to regain compliance with the Nasdaq Minimum Bid Price Rule. There can be no assurance that the Panel will determine to continue to allow the listing of the Company's securities on the Nasdaq Capital Market, or that the Company will consummate a reverse share split. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2024 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.  
            

CMND

Clearmind Medicine Announces 1-for-40 Reverse Share Split

<article>
    <header>
        <h1>Clearmind Medicine (CMND) Announces 1-for-40 Reverse Share Split</h1>
        <p>Vancouver, Canada – December 10, 2025</p>
    </header>
    
    <section>
        <h2>Overview of the Reverse Share Split</h2>
        <p>Clearmind Medicine Inc. (Nasdaq: <strong>CMND</strong>), a clinical-stage biotech company focused on developing innovative therapeutics derived from neuroplastogens, has announced a reverse share split of its common shares at a ratio of 1-for-40. This strategic move aims to help the company regain compliance with the Nasdaq Minimum Bid Price Rule and will take effect on December 15, 2025.</p>
        <p>The reverse split was authorized by Clearmind's board of directors on November 12, 2025, in alignment with the company's articles of association.</p>
    </section>
    
    <section>
        <h2>Impact of the Reverse Share Split</h2>
        <ul>
            <li>The number of issued and outstanding shares will decrease from <strong>59,991,852</strong> to <strong>1,499,796</strong>, pending adjustments for fractional shares.</li>
            <li>No fractional shares will be issued; instead, all fractions will be rounded up to the nearest whole share.</li>
            <li>A proportional adjustment will be applied to the per-share exercise price and the total number of shares available through outstanding options and warrants.</li>
        </ul>
    </section>

    <section>
        <h2>About Clearmind Medicine Inc.</h2>
        <p>Clearmind is a pioneering pharmaceutical biotech company that specializes in the development of psychedelic-derived therapeutics targeting significant health issues, notably alcohol use disorder. The company is dedicated to researching and commercializing psychedelic compounds for use as regulated medicines, foods, or supplements.</p>
        <p>Currently, Clearmind holds an intellectual property portfolio comprising <strong>nineteen</strong> patent families along with <strong>31 granted patents</strong>. The company plans to continue expanding its patent holdings and is actively seeking additional intellectual property to enhance its offerings.</p>
    </section>

    <section>
        <h2>Trading Information</h2>
        <p>Shares of Clearmind Medicine are listed on the Nasdaq under the symbol <strong>CMND</strong> and also traded on the Frankfurt Stock Exchange as <strong>CWY0</strong>.</p>
    </section>

    <section>
        <h2>Contact Information</h2>
        <p>For further inquiries, please contact Clearmind's investor relations:</p>
        <ul>
            <li>Email: <a href="mailto:invest@clearmindmedicine.com">invest@clearmindmedicine.com</a></li>
            <li>Phone: (604) 260-1566</li>
            <li>U.S. Inquiries: <a href="mailto:CMND@crescendo-ir.com">CMND@crescendo-ir.com</a></li>
            <li>General Inquiries: <a href="mailto:info@clearmindmedicine.com">info@clearmindmedicine.com</a></li>
            <li>Website: <a href="https://www.clearmindmedicine.com">clearmindmedicine.com</a></li>
        </ul>
    </section>

    <section>
        <h2>Forward-Looking Statements</h2>
        <p>This article contains “forward-looking statements” as defined by the Private Securities Litigation Reform Act. Terms like “expects,” “anticipates,” and similar phrases are used to indicate future events or outcomes.</p>
        <p>While Clearmind anticipates that the reverse share split will help in meeting Nasdaq requirements, there can be no guarantee regarding the company's continued listing on the Nasdaq Capital Market or the successful execution of this split.</p>
    </section>
</article>

Clearmind announces a 1-for-40 reverse share split effective December 15, 2025.
This split aims to comply with Nasdaq Minimum Bid Price Rule.
Shares will reduce from approximately 60 million to about 1.5 million.
Company plans to enhance its patent portfolio and develop new therapeutics.
Forward-looking statements highlight uncertainty regarding Nasdaq compliance.

Clearmind Medicine Announces 1-for-40 Reverse Share Split

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News